curacle co.,ltd. (the curacle) aktie

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease; and CP01-R01, a first oral endothelial stabilizer–based candidate for companion animal CKD therapy. In addition, the company develops SOLVADYS, proprietary oral small-molecule platform for the treatment of endothelial dysfunction; and EAGLES, a flagship platform of Maptics for next-generation biologics. curacle co.,ltd. was incorporated in 2016 and is headquartered in Seoul, South Korea.